HEK293-CLDN18.2 Cells

Unit

3 x 10^6 cells/ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Transformed cell lines

Organism

Human

Donor History

Transformed/immortalized; non-tumorigenic (HEK293 background)

Growth Properties

Monolayer

,

adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS

,

1 mM sodium pyruvate

,

10 mM HEPES

,

1% NEAA. Add Blasticidin (Blasticidin hydrochloride) to achieve a final concentration of 5 µg/mL. Dissociation reagent: Trypsin-EDTA. Seeding density: 2 to 4 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/HEK293-CLDN18.2-Cells/305986

Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.

HEK293-CLDN18.2 cells are human embryonic kidney 293 (HEK293) cells engineered to stably express human claudin 18 isoform 2 (CLDN18.2), a tight junction-associated transmembrane protein belonging to the claudin family. CLDN18.2 is a gastric lineage-specific isoform normally restricted to differentiated gastric mucosal epithelial cells, where its extracellular domains are largely inaccessible under physiological conditions. In malignant transformation, disruption of epithelial polarity and tight junction architecture exposes CLDN18.2 on the tumor cell surface, leading to its overexpression and accessibility in several cancers, including gastric adenocarcinoma, gastroesophageal junction cancer, pancreatic cancer, and other gastrointestinal malignancies. Because of its highly restricted normal tissue distribution and tumor-associated exposure, CLDN18.2 has emerged as a clinically important therapeutic target in oncology.

HEK293-CLDN18.2 cells are widely used for development and characterization of CLDN18.2-targeted therapeutics, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, CAR-T and CAR-NK cell therapies, and targeted imaging agents. The stable recombinant expression system enables quantitative analysis of antigen binding affinity, epitope specificity, receptor density, internalization kinetics, and target-dependent cytotoxicity. These cells are also commonly employed in flow cytometry assays, reporter assays, antibody screening workflows, and immune effector functional studies designed to evaluate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Because HEK293 cells support robust recombinant membrane protein expression and efficient propagation, they provide a reliable platform for standardized CLDN18.2 assay development and therapeutic validation.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.